Search Follow us

 

Oncology Venture (OV) recently announced the initiation of its open-label Phase II study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with metastatic breast cancer (mBC). The first patient, selected by OV’s 2X-121 drug response predictor (DRP) mRNA biomarker, was dosed in late June 2018. Also, OV announced that its impending merger with the Medical Prognosis Institute (MPI) will happen in September 2018. OV shareholders will own 51% of the new company.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs